

Medication-Assisted Treatment

Information for all network providers

On Jan. 1, 2019, Molina Healthcare joined the Ohio Department of Medicaid (ODM) and other Medicaid Managed Care Plans (MCPs) in eliminating prior authorization (PA) on all brand and generic forms of oral short-acting buprenorphine-containing products for all prescribers of Medication-Assisted Treatment (MAT).

MAT is the use of Food and Drug Administration (FDA) approved medications, in combination with counseling and behavioral therapies, to provide a holistic approach to the treatment of substance use disorders. MAT is effective in preventing opioid overdose.

Buprenorphine Safety Edits and Drug Utilization Review Criteria:

In favor of eliminating PA for all forms of oral short-acting buprenorphine-containing products, ODM and the MCPs will implement safety edits and a retrospective drug utilization review process for all brand and generic forms of oral short-acting buprenorphine-containing products. [Sign up at MolinaHealthcare.com/ProviderEmail.](http://MolinaHealthcare.com/ProviderEmail)

Central Nervous System Agents: Medication Assisted Treatment of Opioid Addiction

No PA Required "Preferred"
BUNAVAIL® buccal film (buprenorphine/naloxone)
BUPRENORPHINE SL tablets (generic of Subutex®)
BUPHRENORPHINE/NALOXONE SL tablets
SUBOXONE® SL film (buprenorphine/naloxone)
ZUBSOLV® SL tablets (buprenorphine/naloxone)

Although the focus of the program is following evidence-based guidelines for the treatment of opioid use disorder, MAT is an effective approach for alcohol use disorder and for smoking cessation.

Molina is working to develop a unique retrospective drug utilization review (DUR) process to identify providers who deliver services consistent with best-evidence treatment guidelines for MAT.

Molina representatives will contact providers who fall outside acceptable standards of care to provide education and support through care coordination services.

Look for additional information on our website under the "Health Resources" tab, under "[Opioid Safety Provider Education Resources.](#)"

We look forward to working with you on providing the best care for our members. If you have any questions regarding this policy, please contact Molina Provider Services at (855) 322-4079 Monday through Friday, 8 a.m. to 5 p.m.

Pharmacy Benefit Changes

Information for providers in the Medicaid and MyCare Ohio networks

Effective April 1, 2019, the following medications will now require Prior Authorization (PA).

- Lifitegrast
- Abaloparatide
- Penicillamine

In This Issue – April 2019

- [Medication-Assisted Treatment](#)
- [Pharmacy Benefit Changes](#)

Questions?

Provider Services – (855) 322-4079
 8 a.m. to 5 p.m., Monday to Friday
 (MyCare Ohio available until 6 p.m.)

Email us at OHProviderRelations@MolinaHealthcare.com

Visit our website at MolinaHealthcare.com/OhioProviders

Connect with Us

www.facebook.com/MolinaHealth
www.twitter.com/MolinaHealth

- Apremilast
- Sarilumab
- Denosumab
- Semaglutide

For more information visit our website and check out the updated [Preferred Drug listing Updates – 04/2019](#) list under the “[Rx Info](#)” tab and for a complete list of medications that require PA view the [Prior Authorization List](#).